UCB struck a licensing agreement to develop Antengene’s ATG‑201, a CD19/CD3 bispecific T‑cell engager aimed at autoimmune diseases, in a deal valued at up to $1.1 billion. The transaction gives UCB exclusive global rights and brings a bispecific TCE platform into its immunology pipeline. Under the deal Antengene will complete first‑in‑human phase I studies and then transfer the asset to UCB for further development; the agreement includes up‑front and milestone payments plus tiered royalties. UCB framed the acquisition as a strategic entry into the TCE modality for immunology, complementing its monoclonal antibody franchise and pushing the company deeper into bispecific therapeutics.